Sotatercept for pulmonary hypertension study
Part of Heart & circulation, Lungs & breathing clinical trials.
This study looks at how well the drug Sotatercept works for people with pulmonary hypertension (high blood pressure in the lungs) in a real-world clinic setting. If you are already taking Sotatercept, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have pulmonary hypertension (high blood pressure in your lungs).
- You are currently being treated with the drug Sotatercept.
- You are able to make your own medical decisions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the drug sotatercept affects blood vessels in the lungs. It may help people with group 1 pulmonary hypertension (high blood pressure in the lungs).
This trial uses a special imaging technique (xenon MRI) to see how well the lungs are functioning in people with pulmonary arterial hypertension (PAH) who are being treated with the drug sotatercept. It aims to understand if the drug improves lung function.
This study is a registry that collects information on people with pulmonary hypertension who are using or starting targeted medications. The goal is to understand how these treatments work in real-world settings and improve care for patients like you.
This study is tracking people with pulmonary hypertension (high blood pressure in the lungs) over time to see how their condition and quality of life change. By joining, you help doctors better understand the disease and improve care for others like you.
This study tests a new medication called sotatercept for people with pulmonary arterial hypertension (PAH) who are already on at least two other PAH treatments. The goal is to see if adding sotatercept can improve symptoms and exercise ability.
This study tests a new drug called sotatercept to help people with pulmonary arterial hypertension (PAH)—a condition where blood vessels in the lungs become too narrow, making the heart work harder. The drug may help improve how well your lungs and heart work together.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.